RPL19 Is a Prognostic Biomarker and Promotes Tumor Progression in Hepatocellular Carcinoma

Abstract

BackgroundHepatocellular carcinoma (HCC) is one of the most common malignancies, and the therapeutic outcome remains undesirable due to its recurrence and metastasis. Gene dysregulation plays a pivotal role in the occurrence and progression of cancer, and the molecular mechanisms are largely unknown.MethodsThe differentially expressed genes of HCC screened from the GSE39791 dataset were used to conduct weighted gene co-expression network analysis. The selected hub genes were validated in The Cancer Genome Atlas (TCGA) database and 11 HCC datasets from the Gene Expression Omnibus (GEO) database. Then, a tissue microarray comprising 90 HCC specimens and 90 adjacent normal specimens was used to validate the hub genes. Moreover, the Hallmark, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases were used to identify enriched pathways. Then, we conducted the immune infiltration analysis.ResultsA total of 17 co-expression modules were obtained by weighted gene co-expression network analysis. The green, blue, and purple modules were the most relevant to HCC samples. Four hub genes, RPL19, RPL35A, RPL27A, and RPS12, were identified. Interestingly, we found that all four genes were highly expressed in HCC and that their high expression was related to a poor prognosis by analyzing the TCGA and GEO databases. Furthermore, we investigated RPL19 in HCC tissue microarrays and demonstrated that RPL19 was overexpressed in tumor tissues compared with non-tumor tissues (p = 0.016). Moreover, overexpression of RPL19 predicted a poor prognosis in hepatocellular carcinoma (p < 0.0007). Then, enrichment analysis revealed that cell cycle pathways were significantly enriched, and bile acid metabolism-related pathways were significantly down-regulated when RPL19 was highly expressed. Furthermore, immune infiltration analysis showed that immune response was suppressed.ConclusionOur study demonstrates that RPL19 may play an important role in promoting tumor progression and is correlated with a poor prognosis in HCC. RPL19 may serve as a promising biomarker and therapeutic target for the precise diagnosis and treatment of HCC in the future.

Identification of MAD2L1 as a Potential Biomarker in Hepatocellular Carcinoma via Comprehensive Bioinformatics Analysis

“…To narrow down the number of “candidate” DEGs and determine potential “key” genes for HCC development [ 30 , 31 , 33 , 34 ], a PPI network of 145 DEGs was constructed to visualize the relationships between genes, followed by functional analysis. Based on their connectivity level, the top ten hub genes identified included CCNB1, MAD2L1, CCNA2, AURKA, ZWINT, HMMR, TPX2, EZH2, and OIP5.…”

Aging-associated long non-coding RNA boosts longevity and reduces the ribosome content of non-dividing fission yeast cells

“…Intriguingly, while mutants in most ribosomal proteins do not appear to affect aging 94 , orthologs of Rpl1901 (RPL19) are among only four ribosomal proteins shown to affect aging in budding yeast and worms where the loss of RPL19 function extends lifespan 95–97 . RPL19 is also among the few ribosomal protein genes that are up-regulated in embryonic stem cells of human blastocysts and hepatocellular carcinoma 98,99 , and post-transcriptional silencing of RPL19 alleviates human prostate cancer by controlling the translation of a subset of transcripts 100 . Ribosomal proteins may affect aging in different ways, e.g.…”

Comprehensive analysis of immunogenic cell death associated genes expression, tumor microenvironment, and prognosis in hepatocellular carcinoma

“…ICD plays an important role in the development of cancers. Several studies have been conducted to explore some of the genes that influence the prognosis of HCC ( Rao et al, 2021 ; Chen et al, 2022 ). However, the role of ICD associated genes in the prognosis of HCC had not been explored.…”